Loading...
Telix Pharmaceuticals Limited
TLX•NASDAQ
Healthcare
Biotechnology
$14.20
$0.31(2.23%)
Telix Pharmaceuticals Limited (TLX) Financial Performance & Income Statement Overview
Review Telix Pharmaceuticals Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
55.85%
↑ 55.85%
Operating Income Growth
418.50%
↑ 418.50%
Net Income Growth
857.95%
↑ 857.95%
Operating Cash Flow Growth
0.00%
Operating Margin
10.49%
↑ 10.49%
Gross Margin
65.08%
↑ 65.08%
Net Profit Margin
6.37%
↑ 6.37%
ROE
13.92%
↑ 13.92%
ROIC
6.93%
↑ 6.93%
Telix Pharmaceuticals Limited (TLX) Income Statement & Financial Overview
Review Telix Pharmaceuticals Limited's (TLX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2019 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|
| Revenue | $7.41M | $6.61M | $5.36M | $5.07M |
| Cost of Revenue | $6.45M | $4.99M | $3.43M | $3.85M |
| Gross Profit | $954115.00 | $1.63M | $1.93M | $1.22M |
| Gross Profit Ratio | $0.13 | $0.25 | $0.36 | $0.24 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $820653.00 | $1.68M | $1.88M | $1.56M |
| Operating Expenses | $820653.00 | $1.68M | $1.88M | $1.56M |
| Total Costs & Expenses | $7.27M | $6.66M | $5.31M | $5.41M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $144821.00 | $99072.00 | $114423.00 | $359223.00 |
| Depreciation & Amortization | $435883.00 | $380022.00 | $371874.00 | $440928.00 |
| EBITDA | -$985351.00 | $619568.00 | $703699.00 | $88749.00 |
| EBITDA Ratio | -$0.13 | $0.09 | $0.13 | $0.02 |
| Operating Income | -$1.42M | $239547.00 | $331826.00 | -$352179.00 |
| Operating Income Ratio | -$0.19 | $0.04 | $0.06 | -$0.07 |
| Other Income/Expenses (Net) | -$127783.00 | -$107944.00 | -$105841.00 | -$376127.00 |
| Income Before Tax | -$1.55M | $131603.00 | $225985.00 | -$728307.00 |
| Income Before Tax Ratio | -$0.21 | $0.02 | $0.04 | -$0.14 |
| Income Tax Expense | $31236.00 | $10351.00 | $8582.00 | $8452.00 |
| Net Income | -$1.58M | $121252.00 | $217403.00 | -$736759.00 |
| Net Income Ratio | -$0.21 | $0.02 | $0.04 | -$0.15 |
| EPS | -$0.14 | $0.01 | $0.02 | -$0.06 |
| Diluted EPS | -$0.14 | $0.01 | $0.02 | -$0.28 |
| Weighted Avg Shares Outstanding | $11.42M | $11.42M | $11.42M | $11.42M |
| Weighted Avg Shares Outstanding (Diluted) | $11.42M | $11.42M | $11.42M | $2.60M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan